JP2015526088A - ナチュラルキラー細胞及びその使用 - Google Patents

ナチュラルキラー細胞及びその使用 Download PDF

Info

Publication number
JP2015526088A
JP2015526088A JP2015527530A JP2015527530A JP2015526088A JP 2015526088 A JP2015526088 A JP 2015526088A JP 2015527530 A JP2015527530 A JP 2015527530A JP 2015527530 A JP2015527530 A JP 2015527530A JP 2015526088 A JP2015526088 A JP 2015526088A
Authority
JP
Japan
Prior art keywords
cells
cell population
progenitor
specific embodiment
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015527530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526088A5 (enExample
Inventor
ロウ エリク
ロウ エリク
カング リン
カング リン
ジャンコビク ウラジミル
ジャンコビク ウラジミル
ズハング キアオクイ
ズハング キアオクイ
アブボト スチュアート
アブボト スチュアート
ジェイ． ハリリ ロバート
ジェイ． ハリリ ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015526088A publication Critical patent/JP2015526088A/ja
Publication of JP2015526088A5 publication Critical patent/JP2015526088A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2317—Interleukin-17 (IL-17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015527530A 2012-08-13 2013-08-13 ナチュラルキラー細胞及びその使用 Pending JP2015526088A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682706P 2012-08-13 2012-08-13
US61/682,706 2012-08-13
US201361799211P 2013-03-15 2013-03-15
US61/799,211 2013-03-15
PCT/US2013/054677 WO2014028453A2 (en) 2012-08-13 2013-08-13 Natural killer cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018132290A Division JP2018183161A (ja) 2012-08-13 2018-07-12 ナチュラルキラー細胞及びその使用

Publications (2)

Publication Number Publication Date
JP2015526088A true JP2015526088A (ja) 2015-09-10
JP2015526088A5 JP2015526088A5 (enExample) 2016-09-23

Family

ID=50101590

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015527530A Pending JP2015526088A (ja) 2012-08-13 2013-08-13 ナチュラルキラー細胞及びその使用
JP2018132290A Pending JP2018183161A (ja) 2012-08-13 2018-07-12 ナチュラルキラー細胞及びその使用
JP2020121929A Withdrawn JP2020188782A (ja) 2012-08-13 2020-07-16 ナチュラルキラー細胞及びその使用
JP2022195426A Pending JP2023036639A (ja) 2012-08-13 2022-12-07 ナチュラルキラー細胞及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018132290A Pending JP2018183161A (ja) 2012-08-13 2018-07-12 ナチュラルキラー細胞及びその使用
JP2020121929A Withdrawn JP2020188782A (ja) 2012-08-13 2020-07-16 ナチュラルキラー細胞及びその使用
JP2022195426A Pending JP2023036639A (ja) 2012-08-13 2022-12-07 ナチュラルキラー細胞及びその使用

Country Status (12)

Country Link
US (1) US20150225697A1 (enExample)
EP (2) EP3722416A1 (enExample)
JP (4) JP2015526088A (enExample)
KR (3) KR20210076150A (enExample)
CN (2) CN105008516A (enExample)
AU (3) AU2013302853A1 (enExample)
BR (1) BR112015003149A2 (enExample)
CA (1) CA2881792C (enExample)
HK (1) HK1211620A1 (enExample)
MX (1) MX2015001871A (enExample)
RU (2) RU2019124982A (enExample)
WO (1) WO2014028453A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017012010A (ja) * 2015-06-26 2017-01-19 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
WO2018110159A1 (ja) * 2016-12-14 2018-06-21 株式会社大塚製薬工場 哺乳動物細胞凍結保存液
JP2019501956A (ja) * 2015-11-05 2019-01-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ 免疫療法に使用するための組成物
JP2019504643A (ja) * 2016-02-01 2019-02-21 グリーン・クロス・ラブ・セル・コーポレイション 細胞の凍結保存のための培地組成物およびその使用
JP2019519486A (ja) * 2016-05-07 2019-07-11 セルラリティ インコーポレイテッド ナチュラルキラー細胞を使用して急性骨髄性白血病および多発性骨髄腫を処置する方法
JP2022528079A (ja) * 2019-03-27 2022-06-08 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物
WO2025225667A1 (ja) * 2024-04-26 2025-10-30 日機装株式会社 凍結された腎細胞凝集体を含むプレート、それを用いた薬物動態検査用キット、毒性検査用キット及び創薬開発用キット

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
CA2930573C (en) * 2013-11-15 2023-12-05 Anthrogenesis Corporation Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
WO2016109668A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
JP2018502115A (ja) * 2014-12-31 2018-01-25 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
EP3280796B1 (en) * 2015-04-09 2019-09-11 Universita' degli Studi di Genova Population of human lymphoid precursors, method for their identification and uses thereof
CA2998292A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
CN106701677A (zh) * 2015-11-18 2017-05-24 深圳爱生再生医学科技有限公司 Nk细胞的体外扩增培养方法
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
KR101866827B1 (ko) * 2016-09-28 2018-07-19 한국원자력의학원 방사선 조사된 말초혈액단핵구를 이용한 고효율 자연살상세포의 제조방법 및 이를 이용한 항암 면역 세포치료제 조성물
CN109983120A (zh) 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物
MX2019007840A (es) * 2016-12-30 2020-08-03 Celularity Inc Celulas asesinas naturales modificadas geneticamente.
US12129487B2 (en) * 2017-03-27 2024-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to obtain lymphoid progenitors
CN107384859A (zh) * 2017-09-05 2017-11-24 四川新生命干细胞科技股份有限公司 一种高纯度nk细胞的分离培养方法
US20200246393A1 (en) * 2017-09-28 2020-08-06 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
CN109593711A (zh) 2017-10-02 2019-04-09 盖米达细胞有限公司 扩增自然杀手细胞部份的扩增方法及用途
CN107904175B (zh) * 2017-12-29 2018-09-25 广州沙艾生物科技有限公司 用于免疫细胞的诱导扩增的培养箱
JP2021525066A (ja) * 2018-05-30 2021-09-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ Ｃａｒ ｎｋ細胞
KR102778139B1 (ko) 2018-07-10 2025-03-10 이뮤너티바이오, 인크. 제대혈로부터 cik nkt 세포의 생성
CN109337870B (zh) * 2018-12-24 2020-07-03 广东暨德康民生物科技有限责任公司 人Vγ9Vδ2T细胞扩增方法与培养基
KR102032384B1 (ko) * 2019-03-05 2019-11-08 주식회사 온코인사이트 제대혈 단핵세포에서의 자연살해세포의 제조 방법
EP3922715A4 (en) 2019-04-17 2022-03-30 CHA Biotech Co., Ltd. NATURAL KILLER CELLS WITH INCREASED ANTI-CANCER EFFECTS AND IMMUNOTHERAPEUTIC USE THEREOF
KR102233660B1 (ko) * 2019-05-15 2021-03-30 (주)포에버엔케이 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트
IT201900023922A1 (it) * 2019-12-13 2021-06-13 Univ Degli Studi Genova Popolazione cellulare progenitrice CD56-CD16+PerfnegCD7- e progenie cellulare NK CD94/NKG2C+KIR+CD57+ originata da detta popolazione cellulare CD56-CD16+PerfnegCD7-, loro ottenimento e loro usi
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法
CN112029722A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种nk细胞培养基及其应用
CN112266900A (zh) * 2020-10-30 2021-01-26 广东康盾生物工程技术有限公司 一种car-nk细胞的培养方法
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN113416701B (zh) * 2021-07-28 2023-05-09 新疆西部赛澳生物科技有限责任公司 一种nk细胞培养基及培养方法
US20250129333A1 (en) * 2021-08-06 2025-04-24 Institute Of Zoology, Chinese Academy Of Sciences RIC cell and preparation method therefor and use thereof
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
CN113801846B (zh) * 2021-09-22 2024-06-04 南京艾尔普再生医学科技有限公司 一种从人诱导多能干细胞分化为自然杀伤细胞的方法
CN114891856B (zh) * 2022-05-16 2025-08-15 武汉科技大学 大队列样本单细胞富集和混样建库测序方法
CN114736859B (zh) * 2022-06-13 2022-08-19 广东先康达生物科技有限公司 一种脐带血nk细胞的培养液及培养方法
WO2024101863A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법
US20240279607A1 (en) * 2023-02-17 2024-08-22 FullHope Biomedical Co., Ltd. Pharmaceutical composition comprising modified natural killer cells and antigen-specific t cells, manufacturing method thereof, and method of using the same
CN117603809A (zh) * 2023-12-06 2024-02-27 威海紫光科技园有限公司 一种应用于nk细胞制备过程中复苏的温度控制方法及系统
CN117946971B (zh) * 2023-12-14 2025-07-15 深圳泽医细胞治疗集团有限公司 一种用于诱导C1型iNKT细胞的培养基、培养方法及其应用
WO2025160465A1 (en) * 2024-01-26 2025-07-31 Celularity Inc. A method of treating signs or symptoms of the aging process
CN118370308B (zh) * 2024-04-18 2025-11-11 维赛(佛山)生物科技有限公司 一种临床用犬自然杀伤细胞冷藏保存液及其制备方法和应用
CN120005821B (zh) * 2025-04-21 2025-07-25 上海华颜医药科技有限公司 一种免疫细胞的培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009422A1 (en) * 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
WO2002064755A2 (en) 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030124091A1 (en) * 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
EP2142642B1 (en) * 2007-03-27 2017-08-09 IPD-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics
WO2012065156A2 (en) * 2010-11-13 2012-05-18 University Of Florida Research Foundation, Inc. Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
US11118165B2 (en) * 2011-03-18 2021-09-14 Glycostem Therapeutics B.V. Generation of NK cells and NK-cell progenitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009422A1 (en) * 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017012010A (ja) * 2015-06-26 2017-01-19 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
JP2019501956A (ja) * 2015-11-05 2019-01-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ 免疫療法に使用するための組成物
JP2019504643A (ja) * 2016-02-01 2019-02-21 グリーン・クロス・ラブ・セル・コーポレイション 細胞の凍結保存のための培地組成物およびその使用
JP2019519486A (ja) * 2016-05-07 2019-07-11 セルラリティ インコーポレイテッド ナチュラルキラー細胞を使用して急性骨髄性白血病および多発性骨髄腫を処置する方法
WO2018110159A1 (ja) * 2016-12-14 2018-06-21 株式会社大塚製薬工場 哺乳動物細胞凍結保存液
JP6353615B1 (ja) * 2016-12-14 2018-07-04 株式会社大塚製薬工場 哺乳動物細胞凍結保存液
US11889829B2 (en) 2016-12-14 2024-02-06 Otsuka Pharmaceutical Factory, Inc. Mammalian cell cryopreservation liquid
JP2022528079A (ja) * 2019-03-27 2022-06-08 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物
JP7335971B2 (ja) 2019-03-27 2023-08-30 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物
WO2025225667A1 (ja) * 2024-04-26 2025-10-30 日機装株式会社 凍結された腎細胞凝集体を含むプレート、それを用いた薬物動態検査用キット、毒性検査用キット及び創薬開発用キット

Also Published As

Publication number Publication date
KR20150063374A (ko) 2015-06-09
MX2015001871A (es) 2015-09-21
AU2019204020A1 (en) 2019-06-27
JP2023036639A (ja) 2023-03-14
WO2014028453A2 (en) 2014-02-20
JP2020188782A (ja) 2020-11-26
KR20220166873A (ko) 2022-12-19
AU2022200976A1 (en) 2022-03-03
CA2881792C (en) 2024-02-27
CN114134113A (zh) 2022-03-04
HK1211620A1 (en) 2016-05-27
RU2015108761A (ru) 2016-10-10
JP2018183161A (ja) 2018-11-22
EP3722416A1 (en) 2020-10-14
RU2019124982A (ru) 2019-09-02
EP2882847A4 (en) 2016-03-23
AU2013302853A1 (en) 2015-03-05
CA2881792A1 (en) 2014-02-20
WO2014028453A3 (en) 2014-10-09
EP2882847A2 (en) 2015-06-17
BR112015003149A2 (pt) 2017-08-08
US20150225697A1 (en) 2015-08-13
CN105008516A (zh) 2015-10-28
KR20210076150A (ko) 2021-06-23

Similar Documents

Publication Publication Date Title
US20220259563A1 (en) Methods of generating natural killer cells
JP2023036639A (ja) ナチュラルキラー細胞及びその使用
AU2015271985A1 (en) Methods of generating natural killer cells
HK40037315A (en) Natural killer cells and uses thereof
HK1261927A1 (en) Methods of generating natural killer cells
HK1185101A (en) Methods of generating natural killer cells
HK1185101B (en) Methods of generating natural killer cells
HK1185099A (en) Methods of generating natural killer cells
HK1185099B (en) Methods of generating natural killer cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180313